Protocol Ledger

NCT05352516 · Phase III · COMPLETED

A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Interventional Phase III clinical trial protocol NCT05352516 sponsored by Shanghai Henlius Biotech in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-17 Enrollment: 514 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05352516
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)514 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05352516
Protocol FieldVerified Registry Value
NCT IdentifierNCT05352516
Consolidated Lead SponsorShanghai Henlius Biotech
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment514 participants (ACTUAL)
Registered Start Date2022-06-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI